<p>Xponance Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度购买了 Guardant Health, Inc. (NASDAQ:GH - 免费报告) 的新头寸。该公司购买了 8,534 股该公司的股票，价值约为 261,000 美元。</p>
<p>获取 <strong>Guardant Health</strong> 警报：</p>
<ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
<p>其他几家对冲基金最近也对该公司的头寸进行了调整。R Squared Ltd 在第四季度以约 26,000 美元的价格购买了 Guardant Health 的新头寸。SBI Securities Co. Ltd. 在第四季度以约 43,000 美元的价格购买了 Guardant Health 的新头寸。Kimelman &amp; Baird LLC 在第四季度以约 58,000 美元的价格购买了 Guardant Health 的新头寸。Jones Financial Companies Lllp 在第四季度将其在 Guardant Health 的持股比例提高了 43.5%。Jones Financial Companies Lllp 目前拥有 2,696 股该公司的股票，价值 82,000 美元，此前在此期间又增持了 817 股。最后，Van ECK Associates Corp 在第四季度将其在 Guardant Health 的持股比例提高了 47.4%。Van ECK Associates Corp 目前拥有 2,887 股该公司的股票，价值 88,000 美元，此前在上个季度又增持了 929 股。92.60% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Guardant Health 价格表现</h2>
<p>Guardant Health 股票周五开盘价为 43.14 美元。该公司的市值为 53.2 亿美元，市盈率为 -12.12，贝塔值为 1.50。Guardant Health, Inc. 的一年低点为 15.81 美元，一年高点为 50.89 美元。该公司的 50 日移动平均线为 44.66 美元，200 日移动平均线为 34.24 美元。</p>
<ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
<p>Guardant Health (NASDAQ:GH - 获取免费报告) 最近于 2 月 20 日星期四发布了其财报。该公司报告本季度每股收益为（$0.90），低于市场共识预期的（$0.75）$0.15。该公司本季度的收入为 2.0181 亿美元，而市场共识预期为 1.9250 亿美元。Guardant Health 的股本回报率为 -19,157.20%，净利润率为 -59.05%。分析师平均预计 Guardant Health, Inc. 本财年的每股收益为 -2.9。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家券商对 GH 发表了评论。摩根大通将 Guardant Health 的目标价从 50.00 美元上调至 55.00 美元，并在 2 月 21 日的报告中给予该股票 “增持” 评级。摩根士丹利将 Guardant Health 的目标价从 42.00 美元上调至 52.00 美元，并在 3 月 6 日的研究报告中给予该股票 “增持” 评级。Canaccord Genuity Group 将 Guardant Health 的目标价从 42.00 美元上调至 60.00 美元，并在 2 月 24 日的研究报告中给予该公司 “买入” 评级。Stifel Nicolaus 将 Guardant Health 的目标价从 45.00 美元上调至 53.00 美元，并在 2 月 21 日的报告中给予该股票 “买入” 评级。最后，高盛集团将 Guardant Health 的目标价从 49.00 美元上调至 56.00 美元，并在 2 月 21 日的研究报告中给予该公司 “买入” 评级。20 位投资分析师对该股票给予了 “买入” 评级，根据 MarketBeat.com 的数据，Guardant Health 目前的平均评级为 “买入”，平均目标价为 48.95 美元。</p>
<ul>
<li>3 只快速增长的股票分析师预计价格翻倍</li>
</ul>
<p><strong>查看我们对 Guardant Health 的最新股票分析</strong></p>
<h2>Guardant Health 公司简介</h2>
<p>（免费报告）</p>
<p>Guardant Health, Inc. 是一家精准肿瘤学公司，在美国和国际上提供血液和组织检测、数据集和分析。该公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 测试；Guardant360 反应测试；Guardant360 TissueNext 测试；GuardantINFINITY 测试；GuardantConnect，一种为临床和生物制药客户设计的集成软件解决方案，旨在将接受检测的患者与具有潜在相关临床研究的可操作性改变相连接；GuardantOMNI 测试用于晚期癌症；以及 GuardantINFORM，一种用于各种生物标志物驱动癌症的肿瘤演变和治疗耐药性的计算机研究平台。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Guardant Health</li>
<li>比较和交易高市盈率股票</li>
<li>为什么 Dollar Tree 的 Family Dollar 出售可能会引发复苏</li>
<li>股息王宝洁在财报后疲软时值得买入</li>
<li>摩根大通：银行业的 “英伟达” 有望获得更多收益？</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>买入 Chewy 股票反转？这是现在的时机</li>
</ul>
<p><strong>想看看其他对冲基金持有 GH 的股票吗？</strong> 访问 HoldingsChannel.com 获取 Guardant Health, Inc. (NASDAQ:GH - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
<p>在考虑 Guardant Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 Guardant Health 并不在名单上。</p>
<p>虽然 Guardant Health 目前在分析师中被评为买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Xponance Inc. 在最近的 13F 文件中报告，在第四季度收购了 8,534 股 Guardant Health, Inc.（纳斯达克代码：GH），价值约为 261,000 美元。其他对冲基金也增加了在 Guardant Health 的持仓。该股票开盘价为 43.14 美元，市值为 53.2 亿美元，每股收益为负（0.90 美元）。分析师设定的目标价格范围为 50 至 60 美元，平均评级为 “买入”，目标价格为 48.95 美元</p>

<p>Xponance Inc. bought a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm bought 8,534 shares of the company's stock, valued at approximately $261,000.</p>
<div class="lb-trans"><p>Xponance Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度购买了 Guardant Health, Inc. (NASDAQ:GH - 免费报告) 的新头寸。该公司购买了 8,534 股该公司的股票，价值约为 261,000 美元。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Guardant Health</strong> 警报：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>Several other hedge funds also recently made changes to their positions in the company. R Squared Ltd bought a new position in Guardant Health during the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health during the fourth quarter valued at approximately $43,000. Kimelman &amp; Baird LLC bought a new position in shares of Guardant Health during the fourth quarter valued at approximately $58,000. Jones Financial Companies Lllp lifted its stake in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after acquiring an additional 817 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in Guardant Health by 47.4% in the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after acquiring an additional 929 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也对该公司的头寸进行了调整。R Squared Ltd 在第四季度以约 26,000 美元的价格购买了 Guardant Health 的新头寸。SBI Securities Co. Ltd. 在第四季度以约 43,000 美元的价格购买了 Guardant Health 的新头寸。Kimelman &amp; Baird LLC 在第四季度以约 58,000 美元的价格购买了 Guardant Health 的新头寸。Jones Financial Companies Lllp 在第四季度将其在 Guardant Health 的持股比例提高了 43.5%。Jones Financial Companies Lllp 目前拥有 2,696 股该公司的股票，价值 82,000 美元，此前在此期间又增持了 817 股。最后，Van ECK Associates Corp 在第四季度将其在 Guardant Health 的持股比例提高了 47.4%。Van ECK Associates Corp 目前拥有 2,887 股该公司的股票，价值 88,000 美元，此前在上个季度又增持了 929 股。92.60% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Guardant Health Price Performance</h2>
<div class="lb-trans"><h2>Guardant Health 价格表现</h2>
</div><p>Shares of Guardant Health stock opened at $43.14 on Friday. The stock has a market cap of $5.32 billion, a price-to-earnings ratio of -12.12 and a beta of 1.50. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The firm's 50-day moving average is $44.66 and its 200 day moving average is $34.24.</p>
<div class="lb-trans"><p>Guardant Health 股票周五开盘价为 43.14 美元。该公司的市值为 53.2 亿美元，市盈率为 -12.12，贝塔值为 1.50。Guardant Health, Inc. 的一年低点为 15.81 美元，一年高点为 50.89 美元。该公司的 50 日移动平均线为 44.66 美元，200 日移动平均线为 34.24 美元。</p>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Guardant Health (NASDAQ:GH - 获取免费报告) 最近于 2 月 20 日星期四发布了其财报。该公司报告本季度每股收益为（$0.90），低于市场共识预期的（$0.75）$0.15。该公司本季度的收入为 2.0181 亿美元，而市场共识预期为 1.9250 亿美元。Guardant Health 的股本回报率为 -19,157.20%，净利润率为 -59.05%。分析师平均预计 Guardant Health, Inc. 本财年的每股收益为 -2.9。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several brokerages have commented on GH. JPMorgan Chase &amp; Co. upped their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, February 21st. Morgan Stanley increased their price target on shares of Guardant Health from $42.00 to $52.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, March 6th. Canaccord Genuity Group lifted their price objective on Guardant Health from $42.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, February 24th. Stifel Nicolaus upped their target price on Guardant Health from $45.00 to $53.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, February 21st. Finally, The Goldman Sachs Group raised their target price on Guardant Health from $49.00 to $56.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health presently has an average rating of &#34;Buy&#34; and an average target price of $48.95.</p>
<div class="lb-trans"><p>几家券商对 GH 发表了评论。摩根大通将 Guardant Health 的目标价从 50.00 美元上调至 55.00 美元，并在 2 月 21 日的报告中给予该股票 “增持” 评级。摩根士丹利将 Guardant Health 的目标价从 42.00 美元上调至 52.00 美元，并在 3 月 6 日的研究报告中给予该股票 “增持” 评级。Canaccord Genuity Group 将 Guardant Health 的目标价从 42.00 美元上调至 60.00 美元，并在 2 月 24 日的研究报告中给予该公司 “买入” 评级。Stifel Nicolaus 将 Guardant Health 的目标价从 45.00 美元上调至 53.00 美元，并在 2 月 21 日的报告中给予该股票 “买入” 评级。最后，高盛集团将 Guardant Health 的目标价从 49.00 美元上调至 56.00 美元，并在 2 月 21 日的研究报告中给予该公司 “买入” 评级。20 位投资分析师对该股票给予了 “买入” 评级，根据 MarketBeat.com 的数据，Guardant Health 目前的平均评级为 “买入”，平均目标价为 48.95 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师预计价格翻倍</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Guardant Health 的最新股票分析</strong></p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p>
<div class="lb-trans"><p>Guardant Health, Inc. 是一家精准肿瘤学公司，在美国和国际上提供血液和组织检测、数据集和分析。该公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 测试；Guardant360 反应测试；Guardant360 TissueNext 测试；GuardantINFINITY 测试；GuardantConnect，一种为临床和生物制药客户设计的集成软件解决方案，旨在将接受检测的患者与具有潜在相关临床研究的可操作性改变相连接；GuardantOMNI 测试用于晚期癌症；以及 GuardantINFORM，一种用于各种生物标志物驱动癌症的肿瘤演变和治疗耐药性的计算机研究平台。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Buy the Chewy Stock Reversal? Here’s Why Now Is the Time</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Guardant Health</li>
<li>比较和交易高市盈率股票</li>
<li>为什么 Dollar Tree 的 Family Dollar 出售可能会引发复苏</li>
<li>股息王宝洁在财报后疲软时值得买入</li>
<li>摩根大通：银行业的 “英伟达” 有望获得更多收益？</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>买入 Chewy 股票反转？这是现在的时机</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 GH 的股票吗？</strong> 访问 HoldingsChannel.com 获取 Guardant Health, Inc. (NASDAQ:GH - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Guardant Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 Guardant Health 并不在名单上。</p>
</div><p>While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Guardant Health 目前在分析师中被评为买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Xponance Inc. 收购了 8,534 股 Guardant Health, Inc.（NASDAQ: GH）的股票